Fuse Medical, Inc. (FZMD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fuse Medical, Inc. (FZMD) trades at $0.02 with AI Score 51/100 (Grade B). Fuse Medical, Inc. manufactures and distributes medical device implants in the United States, focusing on orthopedic and regenerative products. Market cap: $1.48M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for FZMD: FZMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FZMD against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
FZMD: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Fuse Medical, Inc. (FZMD) Healthcare & Pipeline Overview
Fuse Medical, Inc. is a US-based manufacturer and distributor of medical device implants, specializing in orthopedic and regenerative products. Catering to hospitals and medical facilities, the company offers a comprehensive portfolio of implants for orthopedic surgeries, including spinal, extremity, and sports medicine applications, operating with a 4.8% profit margin.
What Is the Investment Thesis for FZMD?
Fuse Medical, Inc. presents a focused investment opportunity within the medical device sector, driven by its specialization in orthopedic and regenerative products. With a P/E ratio of 5.47 and a gross margin of 64.0%, the company demonstrates potential profitability and operational efficiency. Key value drivers include the expansion of its product portfolio and penetration into new geographic markets within the US. Growth catalysts involve strategic partnerships with hospitals and medical facilities, as well as the introduction of innovative implant technologies. Potential risks include competition from larger medical device manufacturers and fluctuations in healthcare spending. Investors should monitor the company's ability to maintain its gross margin and effectively manage its operating expenses.
Based on FMP financials and quantitative analysis
FZMD Key Highlights
Gross Margin of 64.0% indicates efficient cost management in product manufacturing and distribution.
- P/E Ratio of 5.47 suggests the company may be undervalued compared to its earnings.
- Profit Margin of 4.8% demonstrates the company's ability to generate profit from its revenue.
- The company's focus on orthopedic and regenerative products positions it in a growing segment of the medical device market.
- Beta of -1.11 suggests the stock price is less volatile than the overall market.
Who Are FZMD's Competitors?
FZMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CPIVF Captiva Verde Wellness Corp. | $0.03 | -29.77% | $8.42M | 48 |
| PDRX PD-Rx Pharmaceuticals, Inc. | $3.35 | +0.00% | $5.75M | 44 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FZMD's Key Strengths?
Specialized product portfolio in orthopedic and regenerative medicine.
- Established relationships with hospitals and medical facilities.
- Gross margin of 64.0% indicates efficient cost management.
- Focus on serving a specific niche within the medical device market.
What Are FZMD's Weaknesses?
Small market capitalization may limit access to capital.
- Limited number of employees (31) may constrain growth potential.
- Dependence on sub-distributors for market reach.
- OTC listing may reduce investor confidence.
What Could Drive FZMD Stock Higher?
Potential new product launches in the orthopedic implant market.
- Strategic partnerships with hospitals and medical facilities.
- Expansion of distribution network within the United States.
What Are the Key Risks for FZMD?
Financial-distress signal — its Altman Z-Score of 1.53 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger medical device manufacturers with greater resources.
- Fluctuations in healthcare spending and reimbursement policies.
- Stringent regulatory requirements and potential for product recalls.
- Limited financial disclosure due to OTC Other listing.
- Lower trading volumes and wider bid-ask spreads.
What Are the Growth Opportunities for FZMD?
- Expansion of Product Portfolio: Fuse Medical can drive growth by expanding its product portfolio to include innovative implant technologies and regenerative products. The market for advanced orthopedic implants is projected to reach $12 billion by 2028, offering a significant opportunity for Fuse Medical to capture market share through strategic product development and partnerships. Timeline: Ongoing.
- Geographic Expansion within the US: Fuse Medical can pursue growth by expanding its distribution network and sales presence in underserved regions within the United States. The US medical device market is highly fragmented, with regional variations in demand and healthcare practices. By targeting specific geographic areas, Fuse Medical can increase its market penetration and revenue growth. Timeline: Ongoing.
- Strategic Partnerships with Hospitals and Medical Facilities: Fuse Medical can foster growth by establishing strategic partnerships with hospitals and medical facilities to become a preferred supplier of orthopedic implants and regenerative products. These partnerships can provide Fuse Medical with access to a larger customer base and recurring revenue streams. Timeline: Ongoing.
- Focus on Minimally Invasive Surgical Techniques: Fuse Medical can capitalize on the growing trend of minimally invasive surgical techniques by developing and marketing implants specifically designed for these procedures. Minimally invasive surgery offers benefits such as reduced pain, shorter recovery times, and lower healthcare costs, driving demand for specialized implants. Timeline: Ongoing.
- Development of Osteo-biologics and Regenerative Products: Fuse Medical can invest in the development of osteo-biologics and regenerative products to address the increasing demand for tissue repair and regeneration solutions. The market for regenerative medicine is projected to reach $50 billion by 2027, offering a significant growth opportunity for Fuse Medical. Timeline: Ongoing.
What Are FZMD's Competitive Advantages?
- Specialized product portfolio in orthopedic and regenerative medicine.
- Established relationships with hospitals and medical facilities.
- Distribution network across the United States.
- Expertise in manufacturing and distributing medical device implants.
What Does FZMD Do?
Fuse Medical, Inc., based in Richardson, Texas, is a manufacturer and distributor of medical device implants, primarily serving the United States. The company's origins lie in addressing the needs of orthopedic surgeons and patients requiring advanced implant solutions. Over the years, Fuse Medical has evolved to offer a diverse portfolio of orthopedic implants, including internal and external fixation products tailored for foot and ankle procedures, upper and lower extremity plating, and total joint reconstruction implants. The company also provides soft tissue fixation and augmentation solutions for sports medicine procedures, as well as full spinal implants designed for trauma, degenerative disc disease, and deformity indications. Fuse Medical extends its offerings to osteo-biologics and regenerative products, encompassing human allografts, tendons, synthetic skin and bone substitute materials, and regenerative tissues. These products cater to a broad spectrum of surgical needs, solidifying the company's position in the medical device market. Fuse Medical distributes its products to hospitals, medical facilities, and sub-distributors across the United States.
What Products and Services Does FZMD Offer?
- Manufactures orthopedic implants for foot and ankle surgeries.
- Provides internal and external fixation products.
- Offers upper and lower extremity plating solutions.
- Supplies total joint reconstruction implants.
- Develops soft tissue fixation and augmentation products for sports medicine.
- Creates spinal implants for trauma, degenerative disc disease, and deformity indications.
- Offers osteo-biologics and regenerative products, including human allografts and synthetic bone substitutes.
How Does FZMD Make Money?
- Manufactures a range of orthopedic and regenerative medical devices.
- Distributes products directly to hospitals and medical facilities.
- Utilizes sub-distributors to expand market reach.
- Generates revenue through the sale of implants and related products.
What Industry Does FZMD Operate In?
Fuse Medical, Inc. operates within the competitive medical device industry, which is characterized by technological innovation, stringent regulatory requirements, and evolving healthcare practices. The market for orthopedic implants and regenerative products is driven by an aging population, increasing prevalence of chronic diseases, and advancements in surgical techniques. Key competitors include companies like CPIVF (CannAssist International Corp), KOSK (KOSDAQ), PDRX (Pardes Biosciences Inc), PMEDF (Premier Medical Corporation), and RMSL (RMS Lifescience Ltd). Fuse Medical differentiates itself through its comprehensive product portfolio and focus on serving hospitals and medical facilities.
Who Are FZMD's Key Customers?
- Hospitals
- Medical Facilities
- Sub-distributors
Financial Health
Fuse Medical, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.53 places it in the distress zone, a signal of elevated financial risk.
FZMD Valuation & Market Position
With a $1.48M market cap, Fuse Medical, Inc. sits in the micro-cap segment of the market. Relative to its peer group, FZMD's quantitative score of 51/100 is roughly in line with the peer average of 57/100.
Key Financial Metrics
Return on equity for Fuse Medical, Inc. stands at 13.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.5%, showing how much profit it generates from its asset base. FZMD trades at a trailing price-to-earnings ratio of 2.74, below the Healthcare sector average of ~23x. Its free cash flow yield is -14.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 36.5%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Fuse Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Farmers Branch, US. The company is led by CEO Christopher C. Reeg. FZMD has traded publicly since 1999.
FZMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized product portfolio in orthopedic and regenerative medicine.
- Established relationships with hospitals and medical facilities.
- Gross margin of 64.0% indicates efficient cost management.
- Focus on serving a specific niche within the medical device market.
Bear Case
- Small market capitalization may limit access to capital.
- Limited number of employees (31) may constrain growth potential.
- Dependence on sub-distributors for market reach.
- OTC listing may reduce investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
FZMD Latest News
No recent news available for FZMD.
FZMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FZMD.
Price Targets
Wall Street price target analysis for FZMD.
FZMD MoonshotScore
What does this score mean?
The MoonshotScore rates FZMD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Christopher C. Reeg
CEO
Christopher C. Reeg serves as the CEO of Fuse Medical, Inc., leading a team of 31 employees. His background includes extensive experience in the medical device industry, with a focus on strategic leadership and business development. Reeg has a proven track record of driving growth and innovation in the healthcare sector. He is responsible for overseeing all aspects of Fuse Medical's operations, including product development, sales and marketing, and financial management. His expertise lies in identifying market opportunities and developing strategies to capitalize on them.
Track Record: Under Christopher C. Reeg's leadership, Fuse Medical, Inc. has focused on expanding its product portfolio and strengthening its relationships with hospitals and medical facilities. He has overseen the introduction of new implant technologies and the expansion of the company's distribution network. Reeg has also played a key role in managing the company's financial performance and ensuring compliance with regulatory requirements. His strategic decisions have contributed to the company's growth and market position.
FZMD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Fuse Medical, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may be subject to greater risks. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies often have less stringent listing requirements, resulting in increased information asymmetry and potential for speculative trading. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other listing.
- Lower trading volumes and wider bid-ask spreads.
- Increased price volatility and potential for significant price swings.
- Potential for speculative trading and market manipulation.
- Higher risk of fraud or misrepresentation compared to exchange-listed companies.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Review the company's legal and regulatory compliance.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- The company manufactures and distributes medical device implants, indicating a tangible business operation.
- The company serves hospitals, medical facilities, and sub-distributors, suggesting a customer base.
- The company has been in operation for several years, indicating some level of stability.
- The company has a CEO and management team, suggesting organizational structure.
- The company's products are used in orthopedic surgeries, implying a degree of medical relevance.
Fuse Medical, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for FZMD?
FZMD holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Fuse Medical, Inc. manufactures and distributes medical device implants in the United States, focusing on orthopedic and regenerative products. The company serves hospitals, medical facilities, …
What does Fuse Medical, Inc. do?
Fuse Medical, Inc. manufactures and distributes medical device implants, focusing on orthopedic and regenerative products. The company offers a range of implants for various surgical procedures, including foot and ankle, upper and lower extremity, and spinal surgeries. Fuse Medical serves hospitals, medical facilities, and sub-distributors in the United States, providing solutions for trauma, degenerative disc disease, and sports medicine applications.
What do analysts say about FZMD stock?
As of March 16, 2026, formal analyst ratings and price targets for Fuse Medical, Inc. (FZMD) are not widely available, likely due to its OTC listing and smaller market capitalization. Investors should focus on fundamental analysis, monitoring the company's revenue growth, gross margin, and operating expenses.
What are the main risks for FZMD?
Fuse Medical, Inc. faces several risks, including competition from larger medical device manufacturers with greater resources and established market presence. Fluctuations in healthcare spending and changes in reimbursement policies from insurance providers could also impact the company's revenue and profitability. Stringent regulatory requirements and the potential for product recalls pose additional challenges.
What are the key factors to evaluate for FZMD?
Fuse Medical, Inc. (FZMD) holds an AI score of 51/100 (moderate). presents a focused investment opportunity within the medical device sector, driven by its specialization in orthopedic and regenerative products. Not financial advice.
How frequently does FZMD data refresh on this page?
FZMD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven FZMD's recent stock price performance?
Fuse Medical, Inc. (FZMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio in orthopedic and regenerative medicine. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FZMD overvalued or undervalued right now?
Fuse Medical, Inc. (FZMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research FZMD before investing?
Before investing in Fuse Medical, Inc. (FZMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for FZMD.